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Abstract
Background: Cardiovascular health is of increasing concern to breast cancer survivors and their health care providers, as many
survivors are more likely to die from cardiovascular disease than cancer. Implementing clinical decision support tools to address
cardiovascular risk factor awareness in the oncology setting may enhance survivors’ attainment or maintenance of cardiovascular
health.
Objective: We sought to evaluate survivors’ awareness of cardiovascular risk factors and examine the usability of a novel
electronic health record enabled cardiovascular health tool from the perspective of both breast cancer survivors and oncology
providers.
Methods: Breast cancer survivors (n=49) recruited from a survivorship clinic interacted with the cardiovascular health tool and
completed pre and posttool assessments about cardiovascular health knowledge and perceptions of the tool. Oncologists, physician
assistants, and nurse practitioners (n=20) who provide care to survivors also viewed the cardiovascular health tool and completed
assessments of perceived usability and acceptability.
Results: Enrolled breast cancer survivors (84% White race, 4% Hispanic ethnicity) had been diagnosed 10.8 years ago (SD 6.0)
with American Joint Committee on Cancer stage 0, I, or II (45/49, 92%). Prior to viewing the tool, 65% of survivors (32/49)
reported not knowing their level for one or more cardiovascular health factors (range 0-4). On average, only 45% (range 0%-86%)
of survivors’ known cardiovascular health factors were at an ideal level. More than 50% of survivors had ideal smoking status
(45/48, 94%) or blood glucose level (29/45, 64%); meanwhile, less than 50% had ideal blood pressure (12/49, 24%), body mass
index (12/49, 24%), cholesterol level (17/35, 49%), diet (7/49, 14%), and physical activity (10/49. 20%). More than 90% of
survivors thought the tool was easy to understand (46/47, 98%), improved their understanding (43/47, 91%), and was helpful
(45/47, 96%); overall, 94% (44/47 survivors) liked the tool. A majority of survivors (44/47, 94%) thought oncologists should
discuss cardiovascular health during survivorship care. Most (12/20, 60%) oncology providers (female: 12/20, 60%; physicians:
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14/20, 70%) had been practicing for more than 5 years. Most providers agreed the tool provided useful information (18/20, 90%),
would help their effectiveness (18/20, 90%), was easy to use (20/20, 100%), and presented information in a useful format (19/20,
95%); and 85% of providers (17/20) reported they would use the tool most or all of the time when providing survivorship care.
Conclusions: These usability data demonstrate acceptability of a cardiovascular health clinical decision support tool in oncology
practices. Oncology providers and breast cancer survivors would likely value the integration of such apps in survivorship care.
By increasing awareness and communication regarding cardiovascular health, electronic health record–enabled tools may improve
survivorship care delivery for breast cancer and ultimately patient outcomes.
(JMIR Cancer 2021;7(1):e18396) doi: 10.2196/18396
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Introduction
Cardiovascular health is of increasing concern to breast cancer
survivors and their health care providers [1,2], since older,
postmenopausal survivors are more likely to die of
cardiovascular disease rather than of cancer [3,4]. Breast cancer
survivors are at greater risk of death due to cardiovascular
disease, compared to age-matched women without a history of
breast cancer [5]. Chemotherapy (eg, anthracyclines),
monoclonal antibody treatment, hormonal treatments, and
radiation all heighten cardiovascular disease risk among
survivors [1,6], further increasing cardiovascular disease
susceptibility among cancer survivors [5,7,8]. Addressing
cardiovascular health is critical for all breast cancer survivors,
especially those who receive cardiotoxic treatments [2,9,10].
According to 1582 long-term cancer survivors surveyed in
California, 62% were overweight or obese, 55% were
hypertensive, 21% were diabetic, 18% were physically inactive,
and 5% were current smokers [11]. An analysis of these
California cancer registry data highlighted the possible role of
shared risk factors in the development of both cancer and
cardiovascular disease, reporting that cancer survivors tend to
have multiple cardiovascular disease risk factors and that
survivorship care often does not address these risk factors
[11,12]. Early recognition and treatment of cardiovascular risk
factors may be important during survivorship, as this increased
risk of cardiovascular death is evident approximately 7 years
postdiagnosis [2,5].
Despite Institute of Medicine recommendations for adequate
prevention efforts and care coordination for cancer survivors
[13-15], cardiovascular risk continues to be undertreated in this
population [16,17]. The majority of National Cancer Institute
Community Oncology Research Program oncologists we
interviewed (11 of 14) in a pilot study [18] reported
cardiovascular health discussions to be “somewhat” or “very”
important. Yet in general survivorship settings, few referrals
for cardiovascular care are made by oncologists to primary care
providers and cardiologists for guideline-driven follow-up care
[11,16,19,20].
The American Heart Association’s (AHA) definition of
cardiovascular health comprises modifiable risk factors, which
are scored according to Table 1. Improvements in cardiovascular
health can reduce cardiovascular disease and breast cancer
recurrence risk [21-26], and increasing patient and provider
awareness can enhance cardiovascular health [13]. Most cancer
survivors do not meet AHA’s healthy standards in multiple
cardiovascular health components such as body mass index
(BMI), physical activity, diet, smoking, blood pressure,
cholesterol level, and glucose level [2,11,21].
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Table 1. American Heart Association simple 7 measures of cardiovascular health, adapted from [27].
Ideal health Intermediate health Poor health Measures
Health behaviors 
Never or quit >12 months Former ≤12 months Current Smoking status 
<25 kg/m2 25-29.9 kg/m2 ≥30 kg/m2 BMI 
≥150 minutes/week moderate or ≥75
minutes/week vigorous or ≥150 min-
utes/week moderate and vigorous 
1-149 minutes/week moderate or 1-
74 minutes/week vigorous or 1-149
minutes/week moderate and vigorous 
None Physical activity 
4-5 components 2-3 components 0-1 components Healthy diet score 
Health factors 
<200 mg/dL 200-239 mg/dL or treated to goal ≥240 mg/dL Total cholesterol level
Systolic <120 mm Hg 
Diastolic <80 mm Hg 
Systolic 120-139 mm Hg or Diastolic
80-89 mm Hg or treated to goal 
Systolic ≥140 mm Hg or Diastolic
≥90 mm Hg 
Blood pressure 
Blood glucose level
<100 mg/dL 100-125 mg/dL or treated to goal ≥126 mg/dL Fasting plasma glu-
cose 
≤5.6% 5.7%-6.4% or treated to goal ≥6.5% Hemoglobin A1c 
Clinical decision support can provide relevant data to the
point-of-care to prompt appropriate disease management and
referrals [28]. Our team has previously developed, implemented,
and evaluated a cardiovascular health assessment tool, Stroke
Prevention in Health care Delivery Environments (SPHERE),
in the primary care setting [29,30]. Use of SPHERE resulted in
improved BMI and diabetes status in the interventional primary
care clinic but not the control clinic [31]. We refined this tool
based upon feedback received from qualitative interviews with
oncologists [18] and added information about receipt of
potentially cardiotoxic cancer treatments. For this study, we
evaluated the acceptability of the new Automated Heart-Health
Assessment tool (AH-HA, Figure 1) among oncology providers
and the Vigor-Us mobile app (Figure 1) among breast cancer
survivors. We hypothesized that the majority of survivors and
oncology providers would express positive views about the
tools and their use in the cancer survivorship setting.
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Figure 1. Adapted AH-HA tool (top) and the Vigor-Us tool (bottom).
The AH-HA tool was embedded within a simulated electronic
health record environment and was intended to be used mainly
with a cursor pointer (mouse). The Vigor-Us tool was a
responsive web app suitable for both touch and click
interactions, with larger interactivity components. AH-HA did
not collect any data from the interface, whereas Vigor-Us
collected all the information entered during the authenticated
sessions (authenticated users, secure sockets layer–encrypted
database).
Methods
Ethical Approval and Informed Consent
This study was approved by the Wake Forest Health Sciences
Institutional Review Board. All procedures performed in studies
involving human participants were in accordance with the ethical
standards of the institutional research committee and with the
1964 Helsinki declaration and its later amendments or
Weaver et alJMIR CANCER
comparable ethical standards. The Wake Forest Health Sciences
Institutional Review Board approved the study with a waiver
of written informed consent.
Study Eligibility and Data Collection
Eligible survivors included those who were at least 21 years of
age, diagnosed with nonmetastatic breast cancer, and at least 3
months after potentially curative cancer treatment (ie, surgery,
chemotherapy, or radiation), excluding maintenance hormonal
therapy. Additional inclusion criteria included no current
evidence of disease or a history of cancer recurrence, a working
email address, and ability to read medical information in
English. Survivors were ineligible for the study if they had
visual impairments that prohibited them from viewing material
on a tablet device or if they were enrolled in hospice care or
had a life expectancy less than 6 months. Survivors were
identified through clinic appointment schedules and contacted
by a research member prior to their appointment by telephone
or immediately before their appointment in the waiting room.
Eligible providers included medical, radiation, gynecologic,
and surgical oncologists; nurse practitioners, and physician
assistants who provided survivorship care to posttreatment
cancer survivors. A list of eligible oncologists, nurse
practitioners, and physician assistants was procured from the
oncology service line administrators, and providers were emailed
an invitation to participate.
All participants provided informed consent prior to participation,
and the study was approved by the Wake Forest Health Sciences
Institutional Review Board (number 37786). Survivor
participants completed a baseline survey, viewed the Vigor-Us
tool (Figure 1) with their cardiovascular health information on
a tablet computer with the study research coordinator, and then
completed a brief postsurvey. The total research visit time was
15 to 20 minutes. Separate from the survivor assessment,
provider participants were provided with a prototype of the
enhanced AH-HA tool (Figure 1) on a tablet computer,
introduced to the manipulation of slider bars and buttons, and
asked to use the tool as they might with a cancer survivor.
Providers also completed brief assessments before and after
viewing the tool. Both survivor and provider participants
received a US $10 gift card.
Cardiovascular Health Assessment Tools
The AH-HA tool (Figure 1) visualizes data regarding the AHA
Simple 7 modifiable cardiovascular heath factors—BMI,
smoking status, blood pressure, total cholesterol level,
hemoglobin A1c or fasting glucose level, healthy diet, and
physical activity [27]—to promote discussions at the point of
care between breast cancer survivors and oncology providers.
AH-HA was adapted from the SPHERE [30] primary care tool
to include information about receipt of potentially cardiotoxic
chemotherapies (ie, anthracyclines, antimetabolites, hormone
therapy, aromatase inhibitors, monoclonal antibodies,
antimicrotubule agents, alkylating agents, and radiation) [32]
and was designed to be integrated with electronic health records
(EHR) using Fast Healthcare Interoperability Resources [33].
Breast cancer survivors viewed a patient-facing version of the
SPHERE tool designed for personal computers and mobile
devices, the Vigor-Us app (Figure 1). This app did not contain
information about receipt of potentially cardiotoxic
chemotherapies because our clinical advisory group felt that
this information was best discussed with a medical provider.
Measures
Survivor cardiovascular risk information abstracted from the
medical record include weight, height, smoking status, blood
pressure, total cholesterol level, and hemoglobin A1c level;
self-reported factors included smoking, physical activity, and
diet (Table 1). Survivor knowledge of cardiovascular health and
perceived importance and appropriateness of heart health
discussions during oncology care were evaluated with 6
questions assessing confidence in understanding risk of heart
disease, understanding steps needed to improve heart health,
perception that cancer (or heart disease) poses a risk to health,
and desire to talk to a provider (oncologist or primary care
provider) about heart health. Survivors were also asked about
the numerical value of each heart health factor (with “I don’t
know” as an option) and to rate each health factor as high (poor
health), somewhat high (intermediate health), or low-risk (ideal
health) according to Table 1. Following their use of the tool,
survivors completed the same 6 preassessment questions along
with 3 additional questions reflecting acceptability of heart
health discussions with oncologists prior to, during, and after
treatment completion. Survivor tool acceptability was assessed
with 5 questions on a 5-point Likert scale (strongly agree to
strongly disagree) regarding liking the tool, helpfulness, ease
of understanding, picture/diagram improved understanding, and
desire to use this tool with oncologist. Survivors also reported
gender, race and ethnicity, years of education, internet and email
usage, and health literacy [34].
Provider self-reported demographic and practice data included
gender, race/ethnicity, years in practice, and percentage of time
spent in patient care. Provider usability was assessed using 6
questions utilized in our previous study of general internal
medicine physicians [29] assessing useful information,
promotion of effectiveness, ease in accessing needed
information, information meets needs, easy to use, and useful
format. These questions were rated on a 7-point Likert scale
from strongly agree to strongly disagree. Three questions
reflecting potential use of tool prior to, during, and after
treatment completion were rated on a 4-point Likert scale (never,
almost, always, almost always).
Statistical Analyses
For this pilot study, the sample size for the oncology provider
survey (n=20) is driven primarily by feasibility concerns. For
the survivor survey, we estimated power to test the hypothesis
that responses to each Likert scale question are generally
positive, which we defined as testing the alternative hypothesis
that the mean score for each question is greater than 3.5 (where
a score of 3 denotes a neutral response to the question).
Assuming a sample of 50 survivors and a standard deviation of
1.0, we will have >80% power provided the true mean score
for a particular question is 3.9 or greater (roughly corresponds
to an average response of agree).
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We conducted descriptive analyses and summarized oncology
provider and survivor demographics and survey responses with
counts and percentages. Providers’ responses were assessed on
a 7-point Likert scale from strongly disagree to strongly agree;
we categorized responses of 5-7 as agreeing. Survivors’
responses were assessed on a 5-point Likert scale from strongly
agree to strongly disagree; responses of agree or strongly agree
were categorized as agreeing. Wilcoxon signed rank tests were
used to compare breast cancer survivors’ knowledge regarding
their cardiovascular risk factors and perceived importance of
cancer and heart disease before and after viewing the tool.
Comparisons were made individually for each of the 6 questions
included on the questionnaire about cardiovascular risk factor
knowledge and perceived importance and appropriateness of
heart health discussions during oncology care. Sidak correction
for multiple testing were utilized due to the 6 questions; P values
<.0085 were considered significant for these outcomes. We
calculated the percent of survivors who reported “I don’t know”
for each cardiovascular risk factor. Among those who did
respond with a value for their risk factor, we calculated percent
agreement between categorization of objective EHR data and
the survivor’s subjective assessment. Finally, we present
survivor and provider data on usability of the tools. Specifically,
we calculated the percent of survivors and providers who agreed
or strongly agreed with the usability questions, and we presented
data on the preferred timing of the intervention according to
survivors and providers.
Results
Sociodemographic and Health Characteristics of Breast
Cancer Survivors
We enrolled 49 breast cancer survivors (Table 2). An additional
13 survivors were screened and not enrolled (4 did not have an
email address, 6 were not interested, and 3 could not stay after
an appointment). The majority of enrolled survivors (92%) had
an early-stage cancer and were on 11 years postdiagnosis (mean
10.8 years, SD 6); all received surgical treatment, 55% (27/49)
received chemotherapy, and 69% (34/49) received radiation.
With regards to receipt of potentially cardiotoxic cancer
treatments, one-third (17/49, 35%) had received treatment with
an anthracycline; almost half received hormone therapy (24/49,
49%); 45% (22/49) received aromatase inhibitors, 6% (3/49)
received monoclonal antibodies, 29% (14/49) received
antimicrotubule agents, 43% (21/49) received alkylating agents,
and 8% (4/49) received antimetabolites. Almost half of survivors
(23/49, 47%) reported graduating from college, and 96% (47/49)
reported adequate health literacy. Most had a cell phone (47/49,
96%), used the internet (43/49, 88%), and used email almost
every day (34/49, 69%). Almost all, survivors (47/49, 96%)
completed the postvisit assessment and provided cardiovascular
health tool usability data.
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Table 2. Characteristics of breast cancer survivor (n=49) and oncology provider (n=20) participants for usability testing of the AH-HA tool.
Oncology providers (n=20)Breast cancer survivors (n=49)Characteristic
 Age (years), n (%)
N/Aa28 (57)<65
N/A21 (43)≥65
  Sex, n (%)
12 (60) 49 (100) Female
8 (40) 0 (0)Male 
  Race, n (%)
14 (70) 41 (84) White  
2 (10) 4 (8) Black or African American  
1 (5) 1 (2.0) Asian  
3 (15) 0 (0)Southeast Asian  
1 (5) 0 (0)American Indian  
0 (0)2 (4) More than one race  
0 (0)1 (2) Unknown  
2 (10) 2 (4) Hispanic ethnicity, n (%)
N/A10.8 (6.0) Time since cancer diagnosis (years), mean (SD) 
  Cancer treatment received, n (%)
N/A49 (100) Surgery  
N/A27 (55) Chemotherapy  
N/A34 (69) Radiation  
  AJCCb stage, n (%)
N/A4 (8) 0  
N/A23 (47) I  
N/A18 (37) II  
N/A4 (8) III  
  Education level, n (%)
N/A7 (14) ≤High school 
N/A19 (40) Some college  
N/A23 (47) College graduate  
Email use every day or almost every day, n (%) 
N/A34 (69) Yes
N/A15 (31)No
Internet use past 30 days, n (%)
N/A43 (88) Yes
N/A6 (12)No
Adequate health literacy, n (%)
N/A47 (96) Yes
N/A2 (4)No
  Provider type, n (%)
14 (70) N/APhysician (MD or DO) 
6 (30) N/APhysician assistant/nurse practitioner  
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Oncology providers (n=20)Breast cancer survivors (n=49)Characteristic
  Years in practice, n (%)
8 (40) N/A≤5 
4 (20) N/A6-10 
8 (40) N/A≥11 
  Oncology specialty, n (%)
13 (65) N/AHematology 
1 (5) N/ARadiation  
6 (30) N/ASurgical  
  Time spent in direct patient care, n (%)
4 (20) N/A≤50%  
7 (35) N/A51-75%  
9 (45) N/A>75%  
aN/A: not applicable.
bAJCC: American Joint Committee on Cancer.
Cardiovascular Health and Awareness of Breast
Cancer Survivors
Prior to viewing the tool, 90% of survivors (44/49) agreed that
cancer posed a risk to their health, and 84% (41/49) agreed that
cardiovascular disease posed a risk to their health. On average,
only 45% (range 0%-86%) of survivors’ known cardiovascular
health factors were reported to be at an ideal level. More than
50% of survivors reported smoking status (45/49, 92%) and
blood pressure (26/49, 53%) in the ideal category; less than
one-third reported BMI, diet, and physical activity in the ideal
range (Figure 2).
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Figure 2. Proportion of breast cancer survivors (n=49) reporting poor (red), intermediate (yellow), ideal (green), and missing (gray) cardiovascular
health factors. CVH: cardiovascular health.
Prior to viewing the tool, 24% of survivors (12/49) expressed
strong agreement that they understood their risk of
cardiovascular disease; 58% (28/49) agreed. Yet 65% (32/49)
reported not knowing the level for one or more cardiovascular
health factors (range 0-4). Cardiovascular risk factors most
likely to be self-reported as “not known” (Figure 2) included
hemoglobin A1c (44/49, 90%), blood glucose level (32/49, 65%),
cholesterol level (21/49, 43%), blood pressure (7/49, 14%), and
BMI (1/49, 2%). When comparing concordance between the
EHR and self-report for categorization of cardiovascular health
factors as ideal vs nonideal among survivors who knew the
categorization of their factor, 90% of survivors (44/49) were
concordant for BMI, 47% (23/49) were concordant for blood
pressure, 28% (14/49) were concordant for blood glucose level,
and 34% (17/49) were concordant for cholesterol level (Figure
3).
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Figure 3. Survivor characterization of cardiovascular health factors. CVH: cardiovascular health; EHR: electronic health record.
Usability of the Tool Among Breast Cancer Survivors
Usability ratings of the tool by breast cancer survivors are shown
in Figure 4. The majority of breast cancer survivors thought the
tool was easy to understand (48/49, 98%), improved their
understanding (45/49, 92%), and was helpful (45/49, 92%);
94% (46/49) liked the tool and agreed oncologists should discuss
heart health during survivorship care. A majority (34/49, 69%)
would like to use the tool with their oncologist at a future
appointment. There were no differences in usability statistics
by those 65 years and older versus those younger than 65 years.
Figure 4. Usability ratings of the tools among breast cancer survivors and oncology providers. CVH: cardiovascular health.
We also assessed survivors’ perception of cardiovascular risk
before and after viewing the tool (Figure 5). For all variables,
survivors reported that they were in stronger agreement with
the statements after viewing the tool (Figure 5). Significant
changes were observed for understanding of cardiovascular risk
(S=–65, P=.009), understanding steps to improve cardiovascular
health (S=–70.5, P<.001, perception of health risk from
cardiovascular disease (S=–45, P=.007), and desire to discuss
cardiovascular risk with a primary care provider (S=–121,
P<.001). There was no significant change in perception of health
risk from cancer or desire to discuss cardiovascular risk with
an oncologist.
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Figure 5. Proportion of breast cancer survivors (n=47) whose cardiovascular health perceptions changed before and after viewing the assessment tool.
Sociodemographic and Practice Characteristics of
Providers
We enrolled 14 physicians, 2 physician assistants, and 4 nurse
practitioners; 60% (12/20) were female, 70% (14/20) were
White, 10% (2/20) were Black, and 10% (2/20) identified as
Hispanic or Latino (Table 2). Hematology oncology was defined
as the practice specialty for 65% of providers (13/20), 60%
(12/20) had been practicing as an attending for more than 5
years, and 80% (16/20) spent more than 50% of their time in
direct patient care. Only 50% (10/20) reported usually or always
talking to their posttreatment patients about cardiovascular
health, and 35% (7/20) usually or always initiated discussion
about cardiovascular health with posttreatment patients.
However, 95% (19/20) reported it was somewhat or very
important to discuss cardiovascular health with posttreatment
patients. About half of providers (9/20, 45%) reported a high
level of comfort with cardiovascular health discussions.
Usability of the Tool Among Oncology Providers
Usability ratings of the tool by providers are shown in Figure
4. Most providers agreed the tool provided useful information
(18/20, 90%), would help their effectiveness (18/20, 90%), was
easy to use (20/20, 100%), and presented information in a useful
format (19/20, 95%); and 85% of providers (17/20) reported
they would use the tool most or all of the time when providing
survivorship care, with 50% (10/20) reporting the same for




Overall, our results suggest both the need for and suitability of
a tailored cardiovascular health assessment tool to heighten
awareness of cardiovascular health among oncology providers
and breast cancer survivors. We present the first usability data
from breast cancer survivors and oncology providers on the
usability of EHR-integrated cardiovascular health assessment
tools. On average, only 45% of breast cancer survivors’ known
cardiovascular health factors were at an ideal level, most
survivors did not know the value or categorization of at least
one of their cardiovascular health factors, and 94% of survivors
(46/49) thought oncologists should discuss heart health during
survivorship care. Nearly all providers indicated that it was
either somewhat important or very important to discuss
cardiovascular health with posttreatment patients. However,
less than half of providers reported a high level of comfort with
cardiovascular health discussions, and only half reported usually
or always talking to their posttreatment patients about
cardiovascular health. Usability data from providers and
survivors demonstrate positive perceptions of the cardiovascular
health apps; 85% of providers (17/20) reported they would use
the tool most or all of the time when providing survivorship
care. Thus, we conclude that clinical decision support tools such
as AH-HA have potential to provide relevant data to providers
at the point of care to initiate discussions and prompt appropriate
referrals to primary care and cardiology—settings in which
cardiovascular health can be managed effectively.
The use of the AH-HA and Vigor-Us tools are one strategy for
improving risk assessment and personalized cardiovascular
disease prevention in cancer survivorship programs, a research
priority identified by the AHA [2]. A majority of breast cancer
survivors did not know one or more of their cardiovascular
health risk factors, despite a majority expressing agreement
before viewing the tool that they understood their risk of heart
disease. In particular, knowledge gaps exist among survivors
with respect to their hemoglobin A1c and cholesterol values,
which are strong independent predictors of cardiovascular
disease [35]. Self-reported understanding of cardiovascular risk
increased among survivors with use of the tool, and survivors
increased their interest in discussing their heart health with
primary care providers following the use of the tool. This
increased awareness and interest may facilitate linking survivors
back into primary care so these risks can be addressed.
Comparison With Prior Work
Our results are consistent with our previous evaluation of general
cardiovascular health clinical decision support in the primary
care setting. In our previous study [29], providers indicated that
the content and the accuracy of the tool met their needs always
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or most of the time. Primary care providers felt the tool was
clear and presented data in a useful format, was easy to use and
user-friendly, and provided up-to-date information in a timely
manner [29].
Limitations
Limitations of this study include the smaller sample size,
nonrandomized usability assessment, single-institution setting,
and the absence of data regarding the impact of the tool on
cardiovascular health and health care utilization. Although we
focused on breast cancer survivors in this usability study, the
tool may also be appropriate for other survivor populations who
have significant competing risk from cardiovascular disease.
Future testing of this tool should take place in more diverse
multi-institutional settings.
Conclusions
The AH-HA point-of-care EHR-based visualization tool brings
together personalized cardiovascular health and contextual
cancer treatment data to address potential gaps in breast cancer
survivorship care. Our previous SPHERE study [29] suggested
that cardiovascular health clinical decision support tools are
well-received in the primary care setting. Findings from the
current study suggest that oncology providers and breast cancer
survivors would benefit from and value the integration of
cardiovascular health clinical decision support apps in
survivorship care. A newly initiated study will test the
effectiveness and implementation of the AH-HA app in a
clinic-randomized trial in community oncology practices.
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